The Health and Environmental Sciences Institute (HESI) is a non-profit institution whose mission is to collaboratively identify and help to resolve global health and environmental challenges through the engagement of scientists from academia, government, industry, NGOs, and other strategic partners.
HESI values the contributions and expertise of each of our 1,000+ partner scientists from around the globe. Check out some of our most exciting collaborations and highlights below.
The HESI Innovation Prize is an unrestricted cash prize of $80,000 USD with the aim of recognizing a scientist who has improved health equity via their work in one or more of the following areas that are central to HESI’s core operations: (1) safe and effective medicines, (2) food safety and security, (3) chemical and consumer product safety, and/or (4) environmental quality and sustainability.
HESI will be accepting applications from April 1 – June 30, 2021.
Learn more and apply.
In honor of its 50th anniversary, Critical Reviews in Toxicology published a special editorial that lists two RISK21 Committee publications among the journal’s top 25 most read papers. Click here to read the editorial.
“A 21st Century Roadmap for Human Health Risk Assessment”
(Pastoor et al. 2014;44 Suppl 3:1–5)
“Risk Assessment in the 21st Century: Roadmap and Matrix”
(Embry et al. 2014;44 Suppl 3:6–16)
The Botanical Safety Consortium (BSC) was officially convened in November 2019 as the result of a Memorandum of Understanding (MOU) between the US Food and Drug Administration (FDA), the National Institute of Health’s National Institute of Environmental Health Sciences (NIEHS), and HESI, and through a federal funding award to HESI from those agencies. The mission of the BSC is to provide a forum for global scientists from government, academia, consumer health groups, industry, and non-profit organizations to work collaboratively to generate a sound scientific basis for integrating existing safety data and the latest toxicology tools to evaluate safety in botanical dietary supplements.
In 2019, the HESI Cardiac Safety Committee was awarded a U01 grant from the US Food and Drug Administration (FDA) on the “Evaluation of Integrated Human-Relevant Approaches to Identify Drug-Induced Cardiovascular Liabilities.” This grant supports HESI’s role in awarding and managing novel, in vitro experimental studies to develop targeted mechanistic data to inform drug safety assessment for key cardiac “failure modes.” HESI Cardiac Safety Committee members have identified six main failure modes, or CV liabilities contributing to drug attrition.
In June 2020, HESI launched a novel collaboration with clinical and research colleagues around the world to advance more efficient and accessible SARS-CoV-2 testing methods. The PROPAGATE Network, a voluntary global network of lab scientists in these countries, will assess the reproducibility and utility of an extraction-less PCR testing method developed by participating scientists at the University of Washington and University of Vermont. This method has the potential to be used as a screening test that requires fewer experimental resources, lower costs, and less time than traditional PCR analysis.
A genotoxic carcinogen, N-nitrosodimethylamine (NDMA), was detected as a synthesis impurity in some valsartan drugs in 2018, and other N-nitrosamines, such as N-nitrosodiethylamine (NDEA), were later detected in other sartan products. N-nitrosamines are pro-mutagens that can react with ...
MicroRNAs (miRNAs) are small non-coding RNA that regulate the expression of messenger RNA and are implicated in almost all cellular processes. Importantly, miRNAs can be released extracellularly and are stable in these matrices where they may serve as indicators of organ or cell-specific ...
Derivation of Predicted No Effect Concentrations (PNECs) for aquatic systems is the primary deterministic form of hazard extrapolation used in environmental risk assessment. Depending on the data availability, different regulatory jurisdictions apply application factors (AFs) to the ...
Cell-based therapies have been making great advances toward clinical reality. Despite the increase in trial activity, few therapies have successfully navigated late-phase clinical trials and received market authorization. One possible explanation for this is that additional tools and ...